⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CPRX News
Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
globenewswire.com
CPRX
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
globenewswire.com
CPRX
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
globenewswire.com
CPRX
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
globenewswire.com
CPRX
Santhera Appoints Orlando Oliveira as Chief Executive Officer
globenewswire.com
AMGN
AGIO
CPRX
ZENA
Form 8-K/A
sec.gov
CPRX
Form 8-K
sec.gov
CPRX
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
globenewswire.com
CPRX
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
CPRX
Form 8-K
sec.gov
CPRX